|
ATE448226T1
(de)
*
|
2000-09-01 |
2009-11-15 |
Novartis Vaccines & Diagnostic |
Aza heterocyclische derivate und ihre therapeutische verwendung
|
|
KR100732206B1
(ko)
|
2000-09-11 |
2007-06-27 |
노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 |
티로신 키나제 억제제로서의 퀴놀리논 유도체
|
|
US20030028018A1
(en)
*
|
2000-09-11 |
2003-02-06 |
Chiron Coporation |
Quinolinone derivatives
|
|
US7642278B2
(en)
*
|
2001-07-03 |
2010-01-05 |
Novartis Vaccines And Diagnostics, Inc. |
Indazole benzimidazole compounds
|
|
EP1401831A1
(en)
*
|
2001-07-03 |
2004-03-31 |
Chiron Corporation |
Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
|
|
AU2002349477A1
(en)
|
2001-11-26 |
2003-06-10 |
Takeda Chemical Industries, Ltd. |
Bicyclic derivative, process for producing the same, and use
|
|
US6822097B1
(en)
*
|
2002-02-07 |
2004-11-23 |
Amgen, Inc. |
Compounds and methods of uses
|
|
MXPA04012440A
(es)
*
|
2002-06-12 |
2005-04-28 |
Abbott Lab |
Antagonistas de receptor de hormona concentradora de melanina.
|
|
DE10238002A1
(de)
|
2002-08-20 |
2004-03-04 |
Merck Patent Gmbh |
Benzimidazolderivate
|
|
US7825132B2
(en)
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
|
CN100526312C
(zh)
*
|
2002-08-23 |
2009-08-12 |
诺华疫苗和诊断公司 |
苯并咪唑喹啉酮及其应用
|
|
US20050256157A1
(en)
*
|
2002-08-23 |
2005-11-17 |
Chiron Corporation |
Combination therapy with CHK1 inhibitors
|
|
US7470709B2
(en)
*
|
2002-08-23 |
2008-12-30 |
Novartis Vaccines And Diagnostics, Inc. |
Benzimidazole quinolinones and uses thereof
|
|
EP1545529A4
(en)
*
|
2002-09-30 |
2010-03-03 |
Bristol Myers Squibb Co |
NEW TYROSINE KINASE HEMMER
|
|
JP2006511616A
(ja)
*
|
2002-11-13 |
2006-04-06 |
カイロン コーポレイション |
癌の処置方法およびその関連方法
|
|
CN100377709C
(zh)
*
|
2002-11-13 |
2008-04-02 |
希龙公司 |
受体酪氨酸激酶抑制剂的制药用途及相关检测方法
|
|
JP2006516626A
(ja)
*
|
2003-01-28 |
2006-07-06 |
スミスクライン ビーチャム コーポレーション |
化学的化合物
|
|
EP2258365B1
(en)
|
2003-03-28 |
2013-05-29 |
Novartis Vaccines and Diagnostics, Inc. |
Use of organic compounds for immunopotentiation
|
|
US7627675B2
(en)
*
|
2003-05-01 |
2009-12-01 |
Cisco Technology, Inc. |
Methods and devices for regulating traffic on a network
|
|
CN1867334A
(zh)
|
2003-07-22 |
2006-11-22 |
詹森药业有限公司 |
作为c－fms激酶抑制剂的喹啉酮衍生物
|
|
US7872014B2
(en)
|
2003-07-23 |
2011-01-18 |
Exelixis, Inc. |
Anaplastic lymphoma kinase modulators and methods of use
|
|
EP2762475A1
(en)
*
|
2003-11-07 |
2014-08-06 |
Novartis Vaccines and Diagnostics, Inc. |
Pharmaceutically acceptable salts of quinolinone compounds and their medical use
|
|
CN1878766B
(zh)
*
|
2003-11-07 |
2011-08-17 |
诺华疫苗和诊断公司 |
合成喹啉酮化合物的方法
|
|
US20050171172A1
(en)
*
|
2003-11-13 |
2005-08-04 |
Ambit Biosciences Corporation |
Amide derivatives as PDGFR modulators
|
|
WO2005054183A2
(en)
*
|
2003-12-01 |
2005-06-16 |
The Scripps Research Institute |
Quinolinone based protein kinase inhibitors
|
|
CN1960731B
(zh)
*
|
2004-02-20 |
2011-12-07 |
诺华疫苗和诊断公司 |
调节炎性和转移过程的方法
|
|
GB0420722D0
(en)
|
2004-09-17 |
2004-10-20 |
Addex Pharmaceuticals Sa |
Novel allosteric modulators
|
|
US7723340B2
(en)
|
2005-01-13 |
2010-05-25 |
Signal Pharmaceuticals, Llc |
Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
|
|
US7759342B2
(en)
|
2005-01-13 |
2010-07-20 |
Signal Pharmaceuticals, Llc |
Methods of treatment and prevention using haloaryl substituted aminopurines
|
|
US7521446B2
(en)
|
2005-01-13 |
2009-04-21 |
Signal Pharmaceuticals, Llc |
Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
|
|
ES2525670T3
(es)
*
|
2005-01-27 |
2014-12-29 |
Novartis Ag |
Tratamiento de tumores metastatizados
|
|
US7538113B2
(en)
|
2005-02-18 |
2009-05-26 |
Wyeth |
4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
|
|
US7582634B2
(en)
|
2005-02-18 |
2009-09-01 |
Wyeth |
7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
|
|
SI2351772T1
(sl)
|
2005-02-18 |
2016-11-30 |
Glaxosmithkline Biologicals Sa |
Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
|
|
NZ599345A
(en)
|
2005-02-18 |
2013-07-26 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic Escherichia Coli
|
|
US7534796B2
(en)
|
2005-02-18 |
2009-05-19 |
Wyeth |
Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
|
|
WO2006124413A2
(en)
*
|
2005-05-13 |
2006-11-23 |
Novartis Ag |
Methods for treating drug resistant cancer
|
|
BRPI0610355A2
(pt)
*
|
2005-05-17 |
2010-06-15 |
Novartis Ag |
métodos par sintetizar compostos heterocìclicos
|
|
US7531542B2
(en)
|
2005-05-18 |
2009-05-12 |
Wyeth |
Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
|
|
EP2270000B1
(en)
|
2005-05-23 |
2015-07-29 |
Novartis AG |
Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
|
|
US7582636B2
(en)
|
2005-05-26 |
2009-09-01 |
Wyeth |
Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
|
|
WO2007011777A2
(en)
|
2005-07-18 |
2007-01-25 |
Novartis Ag |
Small animal model for hcv replication
|
|
BRPI0617252A2
(pt)
*
|
2005-10-14 |
2011-07-19 |
Hoffmann La Roche |
regime de administração para benzodiazepina 5-2-clorofenil)-1,2-diidro-7-flìor-8-metóxi-3-metil-pira zolo [3,4-b] [1,4]
|
|
CA2628152C
(en)
|
2005-11-04 |
2016-02-02 |
Novartis Vaccines And Diagnostics S.R.L. |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
|
NZ568211A
(en)
|
2005-11-04 |
2011-11-25 |
Novartis Vaccines & Diagnostic |
Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
|
|
JP2009514850A
(ja)
|
2005-11-04 |
2009-04-09 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
アジュバントとして減少した量の水中油型エマルションを有するインフルエンザワクチン
|
|
CN102755645A
(zh)
|
2005-11-04 |
2012-10-31 |
诺华疫苗和诊断有限公司 |
佐剂配制的包含细胞因子诱导剂的流感疫苗
|
|
DE102005054904A1
(de)
*
|
2005-11-17 |
2007-05-24 |
Wacker Polymer Systems Gmbh & Co. Kg |
Verfahren zur Herstellung polyvinylalkoholstabilisierter Latices
|
|
TW200730176A
(en)
*
|
2005-11-29 |
2007-08-16 |
Novartis Ag |
Formulations of quinolinones
|
|
EP1960547A2
(en)
|
2005-12-08 |
2008-08-27 |
Novartis AG |
Effects of inhibitors of fgfr3 on gene transcription
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
NZ570106A
(en)
|
2006-01-27 |
2012-04-27 |
Novartis Vaccines & Diagnostic |
Influenza vaccines containing hemagglutinin and matrix proteins
|
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
|
TW200803855A
(en)
*
|
2006-02-24 |
2008-01-16 |
Kalypsys Inc |
Quinolones useful as inducible nitric oxide synthase inhibitors
|
|
AR059898A1
(es)
|
2006-03-15 |
2008-05-07 |
Janssen Pharmaceutica Nv |
Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
|
|
ATE539079T1
(de)
*
|
2006-03-23 |
2012-01-15 |
Novartis Ag |
Imidazochinoxalinverbindungen als immunmodulatoren
|
|
CA2647100A1
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Methods for the preparation of imidazole-containing compounds
|
|
WO2007109812A2
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Immunopotentiating compounds
|
|
JP2009534303A
(ja)
|
2006-03-24 |
2009-09-24 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー |
冷蔵しないインフルエンザワクチンの保存
|
|
CA2647942A1
(en)
|
2006-03-31 |
2007-11-08 |
Novartis Ag |
Combined mucosal and parenteral immunization against hiv
|
|
AR060358A1
(es)
*
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
|
WO2007124288A1
(en)
|
2006-04-19 |
2007-11-01 |
Novartis Ag |
Indazole compounds and methods for inhibition of cdc7
|
|
ATE522541T1
(de)
|
2006-06-09 |
2011-09-15 |
Novartis Ag |
Bakterielle adhäsine konformere
|
|
CA2657093A1
(en)
|
2006-07-07 |
2008-01-10 |
Steven P. Govek |
Bicyclic heteroaryl inhibitors of pde4
|
|
US8138205B2
(en)
|
2006-07-07 |
2012-03-20 |
Kalypsys, Inc. |
Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
|
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
|
JP2010500399A
(ja)
|
2006-08-16 |
2010-01-07 |
ノバルティス アーゲー |
尿路病原性大腸菌由来の免疫原
|
|
US20100010199A1
(en)
|
2006-09-11 |
2010-01-14 |
Novartis Ag |
Making influenza virus vaccines without using eggs
|
|
US8883790B2
(en)
|
2006-10-12 |
2014-11-11 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
EP2073803B1
(en)
|
2006-10-12 |
2018-09-19 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
AU2007330494B2
(en)
|
2006-12-06 |
2014-03-13 |
Seqirus UK Limited |
Vaccines including antigen from four strains of influenza virus
|
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
|
TW200845978A
(en)
|
2007-03-07 |
2008-12-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
|
|
TW200900065A
(en)
|
2007-03-07 |
2009-01-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
|
|
EP2137184B1
(en)
*
|
2007-04-03 |
2013-05-08 |
Array Biopharma, Inc. |
Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
|
|
CA2685888A1
(en)
*
|
2007-05-09 |
2008-11-20 |
Pfizer Inc. |
Substituted heterocyclic derivatives and their pharmaceutical use and compositions
|
|
KR20100045437A
(ko)
|
2007-06-27 |
2010-05-03 |
노파르티스 아게 |
첨가물이 적은 인플루엔자 백신
|
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
|
NZ584152A
(en)
|
2007-09-14 |
2011-11-25 |
Ortho Mcneil Janssen Pharm |
1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
|
|
SI2203439T1
(sl)
|
2007-09-14 |
2011-05-31 |
Ortho Mcneil Janssen Pharm |
1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
|
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
|
WO2009080694A1
(en)
|
2007-12-20 |
2009-07-02 |
Novartis Ag |
Thiazole derivatives used as pi 3 kinase inhibitors
|
|
EA201071086A1
(ru)
|
2008-03-18 |
2011-04-29 |
Новартис Аг |
Усовершенствованный способ получения вакцинных антигенов вируса гриппа
|
|
AR070924A1
(es)
*
|
2008-03-19 |
2010-05-12 |
Novartis Ag |
Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
|
|
AU2009289784B2
(en)
|
2008-09-02 |
2012-03-22 |
Addex Pharma S.A. |
3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
|
|
WO2010060589A1
(en)
|
2008-11-28 |
2010-06-03 |
Ortho-Mcneil-Janssen Pharmaceuticals, Inc. |
Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
|
|
US8568732B2
(en)
|
2009-03-06 |
2013-10-29 |
Novartis Ag |
Chlamydia antigens
|
|
CA3154626A1
(en)
|
2009-04-14 |
2010-10-21 |
Glaxosmithkline Biologicals S.A. |
Compositions for immunising against staphylococcus aureus
|
|
FR2949344A1
(fr)
|
2009-04-27 |
2011-03-04 |
Novartis Ag |
Vaccins de protection contre la grippe
|
|
TWI410418B
(zh)
|
2009-04-29 |
2013-10-01 |
Ind Tech Res Inst |
氮雜薁化合物、藥學組合物與抑制一細胞中蛋白質激酶之活性的方法
|
|
JO2860B1
(en)
|
2009-05-07 |
2015-03-15 |
ايلي ليلي اند كومباني |
Phenylendazolyl compounds
|
|
BRPI1010831A2
(pt)
|
2009-05-12 |
2016-04-05 |
Addex Pharmaceuticals Sa |
derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
|
|
MY153913A
(en)
|
2009-05-12 |
2015-04-15 |
Janssen Pharmaceuticals Inc |
7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
|
CN102439008B
(zh)
|
2009-05-12 |
2015-04-29 |
杨森制药有限公司 |
1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
|
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
|
US10988511B2
(en)
|
2009-07-07 |
2021-04-27 |
Glaxosmithkline Biologicals Sa |
Conserved Escherichia bacterial IG-like domain (group 1) protein (ORF405) immunogens
|
|
EP4218799A1
(en)
|
2009-07-15 |
2023-08-02 |
GlaxoSmithKline Biologicals S.A. |
Rsv f protein compositions and methods for making same
|
|
SG178035A1
(en)
|
2009-07-16 |
2012-03-29 |
Novartis Ag |
Detoxified escherichia coli immunogens
|
|
US8554514B2
(en)
*
|
2009-09-18 |
2013-10-08 |
Advantest Corporation |
Test apparatus and test method
|
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
|
EP2512476A1
(en)
|
2009-12-18 |
2012-10-24 |
Novartis AG |
Method for treating haematological cancers
|
|
ES2707778T3
(es)
|
2009-12-30 |
2019-04-05 |
Glaxosmithkline Biologicals Sa |
Inmunógenos polisacáridos conjugados con proteínas portadoras de E. coli
|
|
NZ602807A
(en)
|
2010-04-16 |
2014-02-28 |
Novartis Ag |
4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor
|
|
MX2012012051A
(es)
|
2010-04-16 |
2012-11-22 |
Novartis Ag |
Compuesto organico para usarse en el tratamiento de cancer de higado.
|
|
EP2575988A1
(en)
|
2010-05-28 |
2013-04-10 |
Tetris Online, Inc. |
Interactive hybrid asynchronous computer game infrastructure
|
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
|
UY33472A
(es)
|
2010-06-30 |
2012-01-31 |
Novartis Ag |
?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
|
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
|
US8859775B2
(en)
|
2010-09-02 |
2014-10-14 |
Merck Patent Gmbh |
Pyrazolopyridinone derivatives as LPA receptor antagonists
|
|
JO3062B1
(ar)
*
|
2010-10-05 |
2017-03-15 |
Lilly Co Eli |
R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
|
|
WO2012062759A1
(en)
|
2010-11-08 |
2012-05-18 |
Janssen Pharmaceuticals, Inc. |
1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
|
|
PT2649069E
(pt)
|
2010-11-08 |
2015-11-20 |
Janssen Pharmaceuticals Inc |
Derivados de 1,2,4-triazolo[4,3-a]piridina e sua utilização como moduladores alostéricos positivos de recetores mglur2
|
|
JP5852665B2
(ja)
|
2010-11-08 |
2016-02-03 |
ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド |
１，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
|
|
PT2667892T
(pt)
|
2011-01-26 |
2019-06-07 |
Glaxosmithkline Biologicals Sa |
Regime de imunização contra o vsr
|
|
PT2670753T
(pt)
|
2011-01-31 |
2017-01-10 |
Novartis Ag |
Novos derivados heterocíclicos
|
|
RU2013146242A
(ru)
|
2011-03-17 |
2015-04-27 |
Новартис Аг |
Fgfr и его лиганды в качестве биомаркеров рака молочной железы у hr-положительных индивидуумов
|
|
WO2012158613A1
(en)
|
2011-05-13 |
2012-11-22 |
Novartis Ag |
Pre-fusion rsv f antigens
|
|
PH12013502099A1
(en)
|
2011-05-19 |
2017-10-25 |
Novartis Ag |
4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one for use in the treatment of adenoid cystic carcinoma
|
|
EP2554662A1
(en)
|
2011-08-05 |
2013-02-06 |
M Maria Pia Cosma |
Methods of treatment of retinal degeneration diseases
|
|
MX2014003182A
(es)
|
2011-09-15 |
2014-09-22 |
Novartis Ag |
Uso de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidaz ol-2-il]-1h-quinolin-2-ona en el tratamiento de cancer en pacientes con insuficiencia hepática moderada.
|
|
PT2771342T
(pt)
|
2011-10-28 |
2016-08-17 |
Novartis Ag |
Derivados de purina e o seu uso no tratamento de doença
|
|
WO2013063003A1
(en)
|
2011-10-28 |
2013-05-02 |
Novartis Ag |
Method of treating gastrointestinal stromal tumors
|
|
CN104080479B
(zh)
|
2011-11-07 |
2019-11-05 |
葛兰素史密丝克莱恩生物有限公司 |
包括spr0096和spr2021抗原的运载体分子
|
|
MX2014009303A
(es)
|
2012-01-31 |
2014-10-14 |
Novartis Ag |
Combinacion de un inhibidor de rtk con un anti-estrogeno y uso del mismo para el tratamiento de cancer.
|
|
JP6381523B2
(ja)
|
2012-05-16 |
2018-08-29 |
ノバルティス アーゲー |
Ｐｉ−３キナーゼ阻害剤の投与レジメン
|
|
EP2872142A1
(en)
|
2012-07-11 |
2015-05-20 |
Novartis AG |
Method of treating gastrointestinal stromal tumors
|
|
SG11201502197XA
(en)
|
2012-10-02 |
2015-04-29 |
Glaxosmithkline Biolog Sa |
Nonlinear saccharide conjugates
|
|
WO2014058785A1
(en)
|
2012-10-10 |
2014-04-17 |
Novartis Ag |
Combination therapy
|
|
CN103804353A
(zh)
*
|
2012-11-01 |
2014-05-21 |
常辉 |
一类治疗精神分裂症的化合物及其用途
|
|
CA2892688A1
(en)
|
2012-11-30 |
2014-06-05 |
Glaxosmithkline Biologicals Sa |
Pseudomonas antigens and antigen combinations
|
|
EP2764866A1
(en)
|
2013-02-07 |
2014-08-13 |
IP Gesellschaft für Management mbH |
Inhibitors of nedd8-activating enzyme
|
|
JP6669499B2
(ja)
|
2013-02-15 |
2020-03-18 |
カラ ファーマシューティカルズ インコーポレイテッド |
治療用化合物
|
|
WO2014130612A1
(en)
|
2013-02-20 |
2014-08-28 |
Kala Pharmaceuticals, Inc. |
Therapeutic compounds and uses thereof
|
|
US9688688B2
(en)
|
2013-02-20 |
2017-06-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
|
|
WO2014191938A1
(en)
|
2013-05-31 |
2014-12-04 |
Novartis Ag |
Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer
|
|
JO3368B1
(ar)
|
2013-06-04 |
2019-03-13 |
Janssen Pharmaceutica Nv |
مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
|
|
JO3367B1
(ar)
|
2013-09-06 |
2019-03-13 |
Janssen Pharmaceutica Nv |
مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
|
|
WO2015057655A1
(en)
|
2013-10-14 |
2015-04-23 |
Eisai R&D Management Co., Ltd. |
Selectively substituted quinoline compounds
|
|
MD4635C1
(ro)
|
2013-10-14 |
2020-01-31 |
Eisai R&D Management Co., Ltd. |
Compuşi de chinolină substituiţi selectiv
|
|
US9890173B2
(en)
|
2013-11-01 |
2018-02-13 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
CN108530458A
(zh)
|
2013-11-01 |
2018-09-14 |
卡拉制药公司 |
治疗化合物的结晶形式及其用途
|
|
EP2870974A1
(en)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella conjugate vaccines
|
|
CA2930359C
(en)
|
2013-12-06 |
2022-03-01 |
Novartis Ag |
Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
|
|
ES2860298T3
(es)
|
2014-01-21 |
2021-10-04 |
Janssen Pharmaceutica Nv |
Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso
|
|
AU2015208233B2
(en)
|
2014-01-21 |
2019-08-29 |
Janssen Pharmaceutica Nv |
Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
|
|
US20170165230A1
(en)
|
2014-04-09 |
2017-06-15 |
Christopher Rudd |
Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
|
|
KR20170016498A
(ko)
|
2014-06-17 |
2017-02-13 |
버텍스 파마슈티칼스 인코포레이티드 |
Chk1 및 atr 저해제의 병용물을 사용하는 암의 치료 방법
|
|
KR20170045205A
(ko)
|
2014-07-09 |
2017-04-26 |
티씨 바이오팜 리미티드 |
감마 델타 t 세포 및 이의 용도
|
|
GB201506423D0
(en)
|
2015-04-15 |
2015-05-27 |
Tc Biopharm Ltd |
Gamma delta T cells and uses thereof
|
|
KR101693781B1
(ko)
*
|
2014-10-06 |
2017-01-09 |
한양대학교 에리카산학협력단 |
다이플루오로알킬기가 도입된 방향족 화합물의 제조 방법
|
|
US20170304313A1
(en)
|
2014-10-06 |
2017-10-26 |
Novartis Ag |
Therapeutic Combination For The Treatment Of Cancer
|
|
CN104774221B
(zh)
*
|
2015-03-19 |
2017-02-08 |
广西师范大学 |
喹啉酮衍生物的金属配合物及其合成方法及应用
|
|
CN104817535A
(zh)
*
|
2015-03-19 |
2015-08-05 |
广西师范大学 |
一种喹啉酮衍生物及其合成方法及应用
|
|
CN104725431B
(zh)
*
|
2015-03-19 |
2017-05-17 |
广西师范大学 |
喹啉酮衍生物的钴(ⅱ)配合物及其合成方法及应用
|
|
GB201507368D0
(en)
|
2015-04-30 |
2015-06-17 |
Ucl Business Plc |
Cell
|
|
CN107922349B
(zh)
|
2015-08-07 |
2021-05-07 |
哈尔滨珍宝制药有限公司 |
作为fgfr和vegfr抑制剂的乙烯基化合物
|
|
WO2017040963A1
(en)
|
2015-09-03 |
2017-03-09 |
Forma Therapeutics, Inc. |
[6,6] fused bicyclic hdac8 inhibitors
|
|
KR102678021B1
(ko)
|
2015-09-30 |
2024-06-26 |
버텍스 파마슈티칼스 인코포레이티드 |
Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
|
|
RU2018119085A
(ru)
|
2015-11-02 |
2019-12-04 |
Новартис Аг |
Схема введения ингибитора фосфатидилинозитол-3-киназы
|
|
EP3231434A1
(en)
|
2016-04-14 |
2017-10-18 |
Fundacio Centre de Regulacio Genomica |
Method of treatment of parkinsonism
|
|
AU2017324713B2
(en)
|
2016-09-08 |
2020-08-13 |
KALA BIO, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
EP3509421A4
(en)
|
2016-09-08 |
2020-05-20 |
Kala Pharmaceuticals, Inc. |
CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
|
|
EP3509423A4
(en)
|
2016-09-08 |
2020-05-13 |
Kala Pharmaceuticals, Inc. |
CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
|
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
|
CN107935858B
(zh)
*
|
2016-10-12 |
2020-09-08 |
利尔化学股份有限公司 |
5-氟-2-硝基苯酚的制备方法
|
|
WO2019001419A1
(en)
|
2017-06-27 |
2019-01-03 |
Janssen Pharmaceutica Nv |
NEW COMPOUNDS OF QUINOLEINONE
|
|
ES2926518T3
(es)
|
2017-11-24 |
2022-10-26 |
Janssen Pharmaceutica Nv |
Compuestos de pirazolopiridinona
|
|
US11384099B2
(en)
|
2017-11-24 |
2022-07-12 |
Janssen Pharmaceutica Nv |
Pyrazolopyridinone compounds
|
|
CN111448185A
(zh)
|
2017-12-07 |
2020-07-24 |
哈尔滨珍宝制药有限公司 |
一种作为fgfr和vegfr抑制剂化合物的盐型、晶型及其制备方法
|
|
CN109553534A
(zh)
*
|
2018-11-27 |
2019-04-02 |
常州大学 |
一种2-硝基-4-甲氧基苯甲酸的制备方法
|
|
BR112021011571A2
(pt)
|
2018-12-26 |
2021-08-31 |
Janssen Pharmaceutica Nv |
Compostos de tienopiridinona
|
|
US10835531B1
(en)
|
2019-06-18 |
2020-11-17 |
Oncology Venture ApS |
Methods for predicting drug responsiveness in cancer patients
|
|
GB201909191D0
(en)
*
|
2019-06-26 |
2019-08-07 |
Ucb Biopharma Sprl |
Therapeutic agents
|
|
JP2024540411A
(ja)
|
2021-11-08 |
2024-10-31 |
プロジェントス・セラピューティクス・インコーポレイテッド |
血小板由来成長因子受容体（ｐｄｇｆｒ）アルファ阻害剤及びその使用
|
|
WO2025085233A1
(en)
*
|
2023-10-20 |
2025-04-24 |
Ensem Therapeutics, Inc. |
Novel derivatives of quinolinones, and compositions and methods thereof
|